<SEC-DOCUMENT>0001104659-21-065144.txt : 20210512
<SEC-HEADER>0001104659-21-065144.hdr.sgml : 20210512
<ACCEPTANCE-DATETIME>20210512162107
ACCESSION NUMBER:		0001104659-21-065144
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20210512
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210512
DATE AS OF CHANGE:		20210512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		21915425

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2116070d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: center; width: 100%"><DIV STYLE="text-align: center; font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Date of Report (Date of earliest event reported):
May 12, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B>CYCLACEL
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Exact name of registrant as specified in its
charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>0-50626</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>91-1707622</B></FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: center; vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(State or other jurisdiction</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>of incorporation)</B></P></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Commission File Number)</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(IRS Employer</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Identification No.)</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>200 Connell Drive, Suite 1500</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Berkeley Heights, NJ 07922</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Address of principal executive offices and
zip code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Registrant&rsquo;s telephone number, including
area code: (908) 517-7330</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Former Name or Former Address, if Changed Since
Last Report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B>Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see </I>General Instruction
A.2. below): </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.95pt; text-indent: -17.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.95pt; text-indent: -17.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Securities registered pursuant to Section&nbsp;12(b)
of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 97%; border-collapse: collapse; margin-left: 0.25in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 40%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 20%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 40%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name of each exchange on which registered </B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Common Stock, par value $0.001 per share</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">CYCC</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The Nasdaq Stock Market LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Preferred Stock, $0.001 par value</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">CYCCP</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The Nasdaq Stock Market LLC</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 24.5pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Emerging growth company&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"><FONT STYLE="font-size: 10pt"><B>Item 2.02</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Results of Operations and Financial Condition.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The information set forth under this &ldquo;Item
2.02. Results of Operations and Financial Condition,&rdquo; including the exhibit attached hereto, shall not be deemed &ldquo;filed&rdquo;
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference into any
filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Attached as Exhibit 99.1 is a copy of a press release
of Cyclacel Pharmaceuticals, Inc. (the &ldquo;<B>Company</B>&rdquo;), dated May 12, 2021, announcing certain financial results for the
first quarter ended March 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The
Company will conduct a conference call to review its financial results on May 12, 2021, at 4:30 p.m., Eastern Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"><FONT STYLE="font-size: 10pt"><B>Item 9.01</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Financial Statements and Exhibits.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Exhibits.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 50pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><A HREF="tm2116070d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="text-align: justify"><A HREF="tm2116070d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Press release announcing financial results for the first quarter ended March 31, 2021, dated May 12, 2021.</FONT></A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 27%">&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Paul McBarron</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Name:&nbsp;&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Paul McBarron</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Executive Vice President&mdash;Finance,</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer and Chief Operating Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Date: May 12, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2116070d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><IMG SRC="image_001.jpg" ALT=""></TD>
  <TD STYLE="vertical-align: middle; text-align: right; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cyclacel
                                            Pharmaceuticals, Inc.</P></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: rgb(163,163,163) 1pt solid; padding-bottom: 5pt; text-align: center; width: 100%"><IMG SRC="image_002.jpg" ALT=""></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Cyclacel
Pharmaceuticals Reports FIRST Quarter 2021 Financial Results</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B><I>-
Announces IND Authorization by FDA for Fadraciclib, a CDK2/9 Inhibitor, in Solid Tumors -</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B><I>-
Recent Publication Reported that Overactive KRAS Mutants are Impeded by CDK9 Inhibition -</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B><I>-
Following Recent Financing, Cash Runway Extended to Early 2023 -</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B><I>-
Conference Call Scheduled May 12, 2021 at 4:30 p.m. ET -</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.35pt 0pt 174.25pt; text-align: center; text-indent: -2.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><B>Berkeley
Heights, NJ, May 12, 2021</B> - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; &quot;Cyclacel&quot; or the &quot;Company&quot;),
a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results for the
first quarter 2021 and business highlights, including an update on its progress with fadraciclib and CYC140, Cyclacel's novel CDK2/9
and PLK1 inhibitors, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&ldquo;During
the quarter, we have made significant progress in bringing our two oral targeted development candidates into mid-stage clinical development.
Following recent FDA authorization of our IND for oral fadraciclib, we will finalize contract discussions with sites and open our multi-cohort
Phase 1b/2 study in patients with solid tumors,&rdquo; said Spiro Rombotis, President and Chief Executive Officer. &ldquo;We believe
fadraciclib is establishing a strong position among compounds in clinical development that specifically address cancer resistance mechanisms,
including suppression of MCL1, MYC and cyclin E. A recent publication identified potential utility of CDK9 inhibitors in KRAS mutant
colorectal cancer, one of the tumor types in our study. Together with our oral CYC140 PLK1 inhibitor program, which has shown in preclinical
models that KRAS mutant cancers are sensitive to CYC140 inhibition, we hope to provide valuable alternatives to patients with these difficult
to treat malignancies. After strengthening our balance sheet in the quarter, we are executing a precision medicine strategy to achieve
multiple milestones and data read outs over the next two years.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Key Corporate Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CYC065-101
                                            Phase 1b/2 oral fadraciclib in advanced solid tumors</B> - announced that the&nbsp;U.S. Food
                                            &amp; Drug Administration&nbsp;(FDA) has authorized Cyclacel&rsquo;s Investigational New
                                            Drug (IND) application for oral fadraciclib to proceed. This Phase 1b/2 registration-directed
                                            trial includes multiple cohorts defined by histology thought to be sensitive to the drug&rsquo;s
                                            mechanism of action and informed by the clinical activity of fadraciclib in MCL1, MYC and
                                            cyclin E amplified cancers. The cohorts include breast, colorectal (including KRAS mutant),
                                            endometrial/uterine, ovarian cancers and certain lymphomas. The study design also includes
                                            a basket cohort which will enroll patients with relevant biomarkers to the drug&rsquo;s mechanism
                                            regardless of histology.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
recent publication by researchers led by Frank McCormick, PhD of University of California San Francisco and NCI&rsquo;s Frederick National
Lab for Cancer Research reported that overactive KRAS mutants are impeded by CDK9 inhibition<SUP>1</SUP>. These data expand on previous
findings, which show that dual CDK2/9 inhibition is an optimal strategy to treat colorectal cancer<SUP>2</SUP>, that KRAS mutant pancreatic
cancer is sensitive to CDK9 inhibition<SUP>3</SUP>, and that fadraciclib showed efficacy against KRAS mutant lung cancer in preclinical
PDX models<SUP>4</SUP>. Collectively these publications suggest the potential for the therapeutic use of fadraciclib in KRAS-mutated
cancers, including colorectal, lung and pancreatic.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-bottom: 3pt; width: 100pt"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP></FONT>Pui Lai L, et al, <I>SLAS Discovery</I> I-II 2021, https://journals.sagepub.com/doi/abs/10.1177/24725552211008853.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2
</SUP></FONT>Somarelli JA, et al, <I>Mol Cancer Ther</I>, 2020 19 2516. DOI:&nbsp;10.1158/1535-7163.MCT-20-0454.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>3
</SUP></FONT>Blake DR, et al, <I>Science Signalling</I>, 2019, https://pubmed.ncbi.nlm.nih.gov/31311847/.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>4
</SUP></FONT>Kawakami M, et al J Natl Cancer Inst, 2017 109, https://pubmed.ncbi.nlm.nih.gov/28376145/.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 4pt; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 8pt">&thorn;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;&nbsp;200
Connell Drive, Suite 1500, Berkeley Heights, NJ 07922, USA Tel +1 908 517 7330 Fax +1 866 271 3466</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt; color: blue"><U>www.cyclacel.com
</U></FONT><FONT STYLE="font-size: 8pt">&ndash; <FONT STYLE="color: blue"><U>info@cyclacel.com</U></FONT></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CYC140
                                            PLK1 inhibitor program - </B>commenced IND-directed activities and manufacturing of clinical
                                            trial supplies for oral CYC140. Initial data in preclinical models show that KRAS mutant
                                            cancers are sensitive to oral CYC140 inhibition.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Phase
                                            1b/2 Investigator Sponsored Trial (IST) of sapacitabine-olaparib combination in patients
                                            with BRCA mutant metastatic breast cancer &ndash; investigators reported that out of 9 patients
                                            enrolled, 5 have achieved partial response (PR), 3 stable disease (SD), and one patient has
                                            progressed.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Announced
                                            the closing of an underwritten public offering for net proceeds to the Company of approximately
                                            $13.5 million, after deducting placement agent fees and other offering expenses. <FONT STYLE="background-color: white">Existing
                                            and new institutional investors participated in the offering. In addition, the Company received
                                            approximately $4.5 million in the quarter through warrant exercises.</FONT></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Key Near-Term Business Objectives and Expected Timeline</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">1H 2021</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-top: 5pt; width: 0.5in"></TD><TD STYLE="padding-top: 5pt; width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-top: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">First
patient dosed with oral fadraciclib in Phase 1b/2 advanced solid tumor study</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">2H 2021</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-top: 5pt; width: 0.5in"></TD><TD STYLE="padding-top: 5pt; width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-top: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">First
patient dosed with oral fadraciclib in Phase 1b/2 leukemia study</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-top: 5pt; width: 0.5in"></TD><TD STYLE="padding-top: 5pt; width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-top: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">First
patient dosed with oral CYC140 in Phase 1/2 advanced solid tumor study</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">1H 2022&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-top: 5pt; width: 0.5in"></TD><TD STYLE="padding-top: 5pt; width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-top: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">First
patient dosed with oral CYC140 in Phase 1/2 leukemia study</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-top: 5pt; width: 0.5in"></TD><TD STYLE="padding-top: 5pt; width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-top: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Phase
1 data with oral fadraciclib in advanced solid tumor study</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-top: 5pt; width: 0.5in"></TD><TD STYLE="padding-top: 5pt; width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-top: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Update
data from the Phase 1b/2 IST of sapacitabine-olaparib combination in patients with BRCA mutant metastatic breast cancer when reported
by the investigators</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.7pt 0pt 0"><B>Financial Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">As of March 31, 2021, cash and cash equivalents
totaled $47.8 million, compared to $33.4 million as of December 31, 2020. The increase of $14.4 million was primarily due to $18.0 million
of net cash provided by financing activities, offset by net cash used in operating activities of $3.6 million. There were no revenues
for each of the three months ended March 31, 2021 and 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Research and development expenses were $2.6 million for the three
months ended March 31, 2021 as compared to $1.1 million for the same period in 2020. Research and development expenses relating to the
CDK inhibitor program increased by approximately $0.8 million for the three&nbsp;months ended March 31, 2021 as clinical evaluation of
fadraciclib is progressing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">General and administrative expenses for the three months ended March
31, 2021 were $1.7 million, compared to $1.3 million for the same period of the previous year due to an increase in legal and professional
expenses and recruitment costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">Total other income, net, for the three months
ended March 31, 2021 was $0.1 million, compared to $0.9 million for the same period of the previous year. The decrease of $0.8 million
for the three months ended March 31, 2021 is primarily related to income received under an Asset Purchase Agreement with Thermo Fisher
Scientific Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">United Kingdom research &amp; development
tax credits were $0.7 million for the three months ended March 31, 2021, as compared to $0.3 million for the same period in 2020 as a
direct consequence of increased qualifying research and development expenditure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">Net loss for the three months ended March
31, 2021 was $3.5 million, compared to $1.2 million for the same period in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">The Company raised net proceeds of approximately
$13.5 million from an equity financing in March 2021. The Company also received an additional $4.5 million of proceeds from warrant exercises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">The Company estimates that cash resources
of $47.8 million as of March 31, 2021 will fund currently planned programs through early 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Conference call information:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 5pt"><B>Conference ID 2763358 </B>Webcast link</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 5pt">US/Canada&nbsp;call: (877) 493-9121 / international call: (973)
582-2750</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 5pt">US/Canada&nbsp;archive: (800) 585-8367 / international archive: (404) 537-3406&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">For the live and archived webcast, please
visit the Corporate Presentations page on the&nbsp;Cyclacel&nbsp;website at&nbsp;<FONT STYLE="color: Blue"><U>www.cyclacel.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B>About Cyclacel Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">Cyclacel
<FONT STYLE="background-color: white">is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on
cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9
inhibitor, and the anti-mitotic program CYC140, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies.&nbsp;</FONT>Cyclacel's<FONT STYLE="background-color: white">&nbsp;strategy
is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology
indications. For additional information, please visit&nbsp;</FONT><FONT STYLE="color: Blue"><U>www.cyclacel.com</U></FONT><FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><B>Forward-looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white">This news release contains certain forward-looking
statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or
from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding,
among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates, the conduct and results of future
clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors
that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research
and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling,
Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital
requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization
of product candidates. You are urged to consider statements that include the words &quot;may,&quot; &quot;will,&quot; &quot;would,&quot;
&quot;could,&quot; &quot;should,&quot; &quot;believes,&quot; &quot;estimates,&quot; &quot;projects,&quot; &quot;potential,&quot; &quot;expects,&quot;
&quot;plans,&quot; &quot;anticipates,&quot; &quot;intends,&quot; &quot;continues,&quot; &quot;forecast,&quot; &quot;designed,&quot; &quot;goal,&quot;
or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the
risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings
we file with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only
as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information,
future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contacts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1.25in; text-align: left">Company:</TD><TD STYLE="text-align: justify">Paul McBarron, (908) 517-7330,&nbsp;pmcbarron@cyclacel.com</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1.25in; text-align: left">Investor Relations:</TD><TD STYLE="text-align: justify">LifeSci Advisors, LLC,&nbsp;Irina Koffler, (646) 970-4681,&nbsp;ikoffler@lifesciadvisors.com</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&copy; Copyright 2021 Cyclacel Pharmaceuticals, Inc. All Rights Reserved.
The Cyclacel logo and Cyclacel&reg; are trademarks of Cyclacel Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CYCLACEL PHARMACEUTICALS, INC.<BR>
CONSOLIDATED STATEMENTS OF OPERATIONS (LOSS)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(In $000s, except share
and per share amounts)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Revenues:</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total revenues</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Operating expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: left; padding-left: 10pt">Research and development</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1,106</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">2,566</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">General and administrative</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,318</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,739</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,424</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,305</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Operating loss</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,424</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(4,305</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Other income (expense):</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Foreign exchange gains (losses)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">69</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Interest income</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">28</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other income, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">817</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">126</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total other income (expense), net</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">914</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">140</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Loss before taxes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,510</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(4,165</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Income tax benefit</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">290</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">687</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Net loss</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,220</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,478</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Dividend on convertible exchangeable preferred shares</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(50</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(50</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Beneficial conversion feature of Series B preferred stock</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss applicable to common shareholders</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,270</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(3,528</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Basic and diluted earnings per common share:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss per share &ndash; basic and diluted</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1.48</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.50</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Weighted average common shares outstanding</TD><TD STYLE="font-size: 10pt; color: #000000">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: right">859,998</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: right">7,099,037</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CYCLACEL PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONSOLIDATED BALANCE SHEET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(In $000s, except share, per share, and liquidation
preference amounts)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">ASSETS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Current assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: left; padding-left: 0.125in">Cash and cash equivalents</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">33,406</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">47,777</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Prepaid expenses and other current assets</TD><TD STYLE="font-size: 10pt; color: #000000; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: right">2,063</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: right">2,686</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Total current assets</TD><TD STYLE="font-size: 10pt; color: #000000">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: right">35,469</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: right">50,463</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Property and equipment, net</TD><TD STYLE="font-size: 10pt; color: #000000">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: right">106</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: right">173</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Right-of-use lease asset</TD><TD STYLE="font-size: 10pt; color: #000000; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: right">1,227</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: right">1,181</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Total assets</TD><TD STYLE="font-size: 10pt; color: #000000; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: #000000; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: #000000; text-align: right">36,802</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: #000000; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; color: #000000; text-align: right">51,817</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Current liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Accounts payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">514</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">871</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Accrued and other current liabilities</TD><TD STYLE="font-size: 10pt; color: #000000; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: right">1,972</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: right">1,901</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Total current liabilities</TD><TD STYLE="font-size: 10pt; color: #000000">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: right">2,486</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: right">2,772</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Lease liability</TD><TD STYLE="font-size: 10pt; color: #000000; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: right">1,057</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: right">996</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Total liabilities</TD><TD STYLE="font-size: 10pt; color: #000000">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: right">3,543</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: right">3,768</TD><TD STYLE="font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 12px">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Stockholders&rsquo; equity</TD><TD STYLE="font-size: 10pt; color: #000000; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: right">33,259</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; color: #000000; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: #000000; text-align: right">48,049</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: #000000; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Total liabilities and stockholders&rsquo; equity</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">36,802</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">51,817</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SOURCE: Cyclacel Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !, ,@# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_7)R< \
M<''KZ#OC//Z8K.DG=9)<^8H5W"DF(*<! F&*DKEB=I;."/F.W&;1D<;\[ !W
MP0<]@2&R.>.A&,@\#%?C=_P4S_X*4)^R]!<?![X03V%]\=M7T^+4-8URZCLK
MS2?A1H&HP2O9W]Y:3RRQW_C/4T6"[T'1+^W73;'39H]?UMI%FT;2M:^CX1X4
MSKCC/\#PUP[@_KF9XZ<G'GE*GA<)A*/++%9CCJZBZ>'P.&I34JE:K?FE*%.A
M1Q%><*9\5Q_QYPUX;<,9AQ;Q7F#P.49=%1Y:2A4Q>88VLI1P66990<HU,7F6
M)K12P^'IKV:4:E;'3H8&CB*T/L']J#]NOX _LFP2Q?$WQK%<>+[BQCO="^&7
MAE;77/'>MQ;"!.-,A:*#0K"1V!_M?Q+?Z5ITHBECM'N+KRK>7\)_C'_P7/\
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MV3D=3N*ESP,D$AN,C)W @8(- $M%0&= .0X!(4,48+EB54[F 49884$Y8E0
M2Z BSI)D*LAX&2$<+R2.&P"1D?> QWSP< $]%0><JML*N'PS!2N"P#+N*8SO
M +J"PXRR[BI:I$?>,[67DC#@JW!QG'H>WJ.: 'T49Q_GKWX]>*K_ &A0%)63
MG=C*$;BN>AZ$LH+J 3E?F.T!L %BBF-(JIYA/R\'\SC_ .OGICD<4T2Y&=DG
M7! 3Y@<D$$ GIC!()'(/3F@"6BH&F56V[)2S9 PA.=I/J0!GDKG (!(/%/9^
M,;'.3MQM..>.?1?4X( H DHJ#SUR<1RDA<L=AX V'!YSG]X<  D[9.RYIEPV
MZUDD3S"?+)41DI*Q!!\M3M8HSD!,[25)R.10!:HK\B_@]^VG^T/XR^-FB>!O
M$_PEU+3?#6K>)]+TJ'5I[2"RT_Q0^NZ-X U+QCX1\&V:EO$^E^)_V6M4\5>)
M]'^,MWXNC\G5#\.=52WTW3;OQ*(/ 10!Y1H.FS>-/^"XOQ U+6O-O(_A+^S_
M &*^%CYZJNGQZAX#\&[;8)NW/')=_$OQ?<JB!0D]\TQ W;F],^$>GVGBO_@K
M3^UWXXU6(27?P;^!'PE^'_AUFA2:""#QI:Z'XDU&[,SJ6@U#;I]S8QFWV&2Q
MU*_BE+(Y%5Y-(M/ /_!9X7_E):VOQV_9!EU.&>XE5FU;Q=X-UH:%JMI8PJP9
M9;/PAX*\/3SJ%*M'')('# A?5?!EI;^!/^"FGQVT^>V:.'X]_LQ?#'XAZ2R#
M-KJ&H?"?Q9?> ?%4$\DJ+LU2VM==\.316]N90=.>XNYUC\I=W[UG&8)9=/ZN
MYVQ/T9N&<'@9).,J<,-G.7SXF5#D:2C.669I.NX/WJ=;$*LFI,_DW),KD\TJ
M>U5*,L/]+?B[%9E]84G&IB\?PQCUP=6G=)2]AB,;DT<,ZCY*<H4Y4;34&?!?
MP?\ !S^.?V O@GH$S3P7?_!03]KS3_$/Q>U""XOWURY\*^,O'WB'QQX@T>XN
MX+DSRN?!'PLL/!M]YLHM8])O-6EE@+3W+R_I+^SCX$TWQI\5_C7^T1JEA:W%
M_IWC#Q)^SK\&5AC?[%\/_A'\$]9E\$ZWI_AFP9(SHUUXN^(^E>++WQ$T4,,M
M[I^EZ'I\#7.BV=I+<_+?PZTF+P7^RO\ #^ 0O8W7[!?[6FI:?XNT6RS//#X&
M\(^/?$N@ZKJ DN(Q+;01_!/XMVGQ"AC>&62\TFP^RK/;F\-]:?H#\"+:T\&:
MW\6OAH&MHKFV^(?C/XI^'X[?Y+;6?!WQA\2:OXW76;1VE9;E[+QGJ7BO0-8D
M@W1P7=I9W#I'%JMF9/%X[SRMB:G$_P!2KSHT<=Q'Q=5F\-'V3GE^89[D+P\(
MUJ+35.MPA@N#<'5I:TEE6&I814OJKK0GZOA=PW1AC.#JV98=5OJ/#/!M2'UF
MM&K.EF.4\*Y]1H2K4:].<E]7XXQOB)BL-I&I3S[GQ[?UJG1G3^@(K>9Y TGF
MJ8Y2H9A(BD (OR@>4@&YLIDS)MW%3G('R+XU_P"$W_:8L_%OPN\#R>*_ ?P+
M\<_#K]H/X2^.OV@O#.L_$#X(_M-_"?XNZ9K=K\/M+G^"/AKQ]\+XHKNQV-XL
M\0:!\8H[Z[\,37N@>&];\*V?BWPSK$&J3?:85>2S@!L'&5![#)W=NV,;2.",
M@4;(D=7\S+#<$!93A692RKD[MH.,(#L "_("JD?CL5&+;BTI.ZE*+Y')62<9
M1C/EY>51CR*,(**]V$%.47_3$80M'GC%M6G'FC&7))-N4J2DI^R3FVY<DG'F
MNU."Y(PXOP+\/M!\$Z7:Q64,VH^('T/PQH7B3QWKD.G3^/O'_P#PB&BV^@Z1
MKOC_ ,0V.G:;-XD\0M8VP>>]NX$CBGGN5L;>SMI! .\5 GW<X('!).,<#&<G
MGG//)YZYI0ZMT(..N#T[>U.JMM//\?3SMV1K\G?SO?YWU_KJ>+_M$?&[P/\
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M#6UI_!H^*?[06K1^%-"TWQ+J6CVES<W%Q?>*-+6W\/>/K&UM4_8^_8H_;?\
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M]15Z[^K4:=:EE>5\54\MHXK$\-<3X# U9Y?A<ZGE>)R3B3+)J4J&9931P/\
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M<OXF?M'?\$!?V&_CW\:/$_[2'@;6_P!HK]B_X_\ CNXDN_'WQ:_8>^,]_P#
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M#Z#^5 Z#Z"OGDM+^GY?U_2/T.UOR[_U]PM%%%, HHHH **** "BBB@ HHHH
..**** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  5 9 # 2(  A$! Q$!_\0
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4LN[D 1//*P*!"2YW$@  HH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
